ClinicalTrials.Veeva

Menu

Analgesic Effect of Ropivacaine Combined With Hydromorphone for CSEA After Total Knee Arthroplasty

J

Jilin University

Status

Completed

Conditions

Postoperative Analgesia

Treatments

Drug: Hydromorphone was injected into the subarachnoid space

Study type

Interventional

Funder types

Other

Identifiers

NCT06205199
2ed hosp JLU ana dept

Details and patient eligibility

About

The aim of this study is to investigate the continuous analgesic effect and side effects of ropivacaine combined with hydromorphone for combined spinal-epidural anesthesia(CSEA) after total knee arthroplasty and to explore its clinical application value. To observe whether hydromorphone combined with ropivacaine can promote the rapid recovery of patients.

Full description

For patients undergoing total knee arthroplasty, different spinal anesthesia drugs were injected in the two groups. The spinal anesthetic drugs injected in the hydromorphone group were hydromorphone 50 μg and ropivacaine 15 mg. In the control group, the spinal anesthetic was ropivacaine 15 mg.The differences in analgesia, sedation, and side effects between the hydromorphone group and the control group were analyzed by collecting various data at different times after anesthesia.

Enrollment

136 patients

Sex

All

Ages

55 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 55 and 80 years old.
  • ASA grade I to III.
  • BMI:20-29kg/m2.
  • No recent use of sedatives, opioids, or other analgesics.
  • There was no contraindication of spinal anesthesia, severe dysfunction of heart, lung and other important organs or serious systemic diseases.
  • Patients were willing to participate in the study and signed the informed consent.

Exclusion criteria

  • The patient has mental illness or cannot cooperate with the completion of spinal anesthesia.
  • The patient had a history of spinal surgery and spinal deformity.
  • Patients had a history of opioid intolerance or adverse reactions.
  • puncture site infection, coagulopathy or recent use of anticoagulant drugs.
  • History of allergy to local anesthetics.
  • Failed puncture.
  • Unable to cooperate to complete the research process.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

136 participants in 2 patient groups

Hydromorphone group
Experimental group
Description:
Hydromorphone 50 micrograms combined with ropivacaine 15 mg was injected into the subarachnoid space
Treatment:
Drug: Hydromorphone was injected into the subarachnoid space
Control group
No Intervention group
Description:
Ropivacaine 15 mg was injected into the subarachnoid space

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems